Search results for Ocrevus

Ocrevus (ocrelizumab) for multiple sclerosis

Ocrevus (ocrelizumab) is an infusion therapy approved to treat adults with relapsing forms of MS and primary progressive MS. Administered via an intravenous infusion, the treatment...

Ocrelizumab Effective In Slowing Progressive MS, Trial Shows

FRIDAY, May 29, 2026 — An already-approved MS drug can significantly slow progression in people with primary progressive multiple sclerosis (PPMS), according to a new study. Patien...

AAN 2026: Ocrevus treatment slows disability in advanced PPMS

Ocrevus (ocrelizumab) delayed disability progression and worsening hand function among a large group of people with primary progressive multiple sclerosis (PPMS), including those w...

In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS

The U.S. Food and Drug Administration (FDA) has approved the infusion therapy Ocrevus (ocrelizumab) for treating children with relapsing-remitting multiple sclerosis (RRMS) who are...

Switching made easier

Schoof LG, Hogenboom L, van Kempen ZL, Killestein J, van Oosten BW, Strijbis EM. Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increa...

AAN 2026: Ocrevus preserves walking, hand function in early RRMS

First-line treatment with Ocrevus (ocrelizumab) preserved walking abilities and hand function in most people with early relapsing-remitting multiple sclerosis (RRMS) over six years...

Drug Effective In Slowing Progressive MS, Trial Shows

FRIDAY, May 29, 2026 — An already-approved MS drug can significantly slow progression in people with primary progressive multiple sclerosis (PPMS), according to a new study.Patien...

AAN226. Ocrelizumab and ADA. Is it too good to be true?

Anti-drug antibodies can stop drugs from working and can cause infusion reactions. They are rare to common occurrances due to the target the drug, the person, the assay, the report...

<![CDATA[ Implications of Tecvayli Plus Darzalex Faspro Demonstrating 83% Reduction in Disease Progression or Death.]...

Blenrep

Blenrep Anonymous (not verified) Thu, 05/28/2026 - 11:40 field_thread_url https://cafepharma.com/boards/threads/blenrep.714532/ board na...

EMA grants PRIME status to new optic neuritis therapy privosegtor

The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multipl...

When is Nothing Different from Nothing? Comparing rituximab and ocrelizumab efficacy

The idea for CD20 immunotherapy is…. deplete the B cells in the circulation and they cannot get into the CNS. If they do not get into the CNS there will be no/few lesions and no/fe...

Frexalimab AAN20226

Frexalimab is an indirect B cell inhibitor. It block the natural signal that a B cell gets from T cells and antigen presenting cells as it blocks the ligand (binding bit) to the CD...

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-ar...

Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the s...

AAN2026. Barrier to treatment for Ocrelizumab

MS treatments are expensive and it is OK if you live in a place with Social Medicine but in many parts of the World one of the features that limits access to treatments is economic...

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antit...

AAN 2026 The First BTK inhibitor for PPMS to Make-It?

So it looks like Fenebrutinib may make it where other BTK inhibiotrs has so far failed. The drug inibits relapsing and primary progressive MS in regard to primary progressive MS it...

Privosegtor optic neuritis clinical trial design gains FDA agreement

The U.S. Food and Drug Administration (FDA) has formally agreed that the design and planned analysis of an upcoming Phase 3 trial testing privosegtor in people with optic neuritis...

MS drugs in the media

News Multiple sclerosis: Could Roche’s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS? BMJ 2026; 393 doi: https://doi....

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-ar...

Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the s...

FDA OKs Immgolis as first golimumab biosimilar for UC, RA

The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis.Golimumab-sldi (Immgolis, Accord BioPharma) has been approved as a bio...

FDA and EMA Accept Teva’s Omalizumab Biosimilar Applications

On March 30, 2026, Teva announced that the FDA and the European Medicines Agency (EMA) accepted regulatory submissions for its proposed biosimilar to Xolair® (omalizumab), TEV-4577...

AAN2026 CLAD 5 years on. What to Do?

With Alemtuzumab about 50% of people need a thrid dose because of disease breakthrough and only about 50% of them would need a forth course because of disease breakthrough. The res...